id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-345689-5ns1onkw	Kusters, Inca C.	Manufacturing Vaccines for an Emerging Viral Infection–Specific Issues Associated with the Development of a Prototype SARS Vaccine	2009-01-30		.txt	text/plain	6218	287	42	Taking into account all the uncertainties and anticipating the worst-case scenario, many laboratories and vaccine manufacturers started working on a vaccine approach against SARS infection, largely based on what was known from animal CoVs. In this chapter, we will discuss the necessity for international cooperation and the importance of discretionary funding for rapidly developing a prototype vaccine candidate. When the laboratory work on the SARS-CoV vaccine development started, no data were available on the inactivation characteristics of the virus. The results from the experiments performed to evaluate the viral loss of the SARS-CoV due to drying on glass surface were also surprising: 35 -42 days were necessary to inactivate the virus to the detection limit of the technique. Based on our experience to date, the inactivated, adjuvanted SARS-CoV prototype vaccine seems to be a good candidate for further evaluation in Phase 1 studies.	./cache/cord-345689-5ns1onkw.txt	./txt/cord-345689-5ns1onkw.txt